Literature DB >> 308196

Safety and clinical efficacy.

C V Burton.   

Abstract

When applied under the circumstances of minimal patient risk documented in this paper, implanted neuroaugmentive spinal devices are a reasonable means of therapy for selected severe pain problems. With presently developed screening techniques, in 198 patients predominantly suffering from failed back surgery syndrome, a 50% good-to-excellent result was obtained. These figures represent a very significant improvement in the success of treatment for this group of patients when compared to other present modes of therapy. With continued optimization of the use of spinal neuroaugmentive devices, it is likely that clinical success can be further improved in the future.

Entities:  

Mesh:

Year:  1977        PMID: 308196

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  4 in total

1.  Spinal cord stimulation in 60 cases of intractable pain.

Authors:  B A Simpson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

2.  Spinal cord stimulation in patients with a battered root syndrome.

Authors:  H Waisbrod; H U Gerbershagen
Journal:  Arch Orthop Trauma Surg       Date:  1985

3.  Spinal cord stimulation for failed back surgery syndrome.

Authors:  Jean-Christophe Leveque; Alan T Villavicencio; Ketan R Bulsara; Linda Rubin; John P Gorecki
Journal:  Neuromodulation       Date:  2001-01

4.  Persistent Spinal Pain Syndrome: A Proposal for Failed Back Surgery Syndrome and ICD-11.

Authors:  Nick Christelis; Brian Simpson; Marc Russo; Michael Stanton-Hicks; Giancarlo Barolat; Simon Thomson; Stephan Schug; Ralf Baron; Eric Buchser; Daniel B Carr; Timothy R Deer; Ivano Dones; Sam Eldabe; Rollin Gallagher; Frank Huygen; David Kloth; Robert Levy; Richard North; Christophe Perruchoud; Erika Petersen; Philippe Rigoard; Konstantin Slavin; Dennis Turk; Todd Wetzel; John Loeser
Journal:  Pain Med       Date:  2021-04-20       Impact factor: 3.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.